FDA Panel Supports Broadening Access to Peptides Popular on the Gray Market

Popular peptide therapies that lack FDA approval and robust human clinical evidence could become more widely available if federal regulators move forward with recommendations to allow compounding pharmacies to produce them.

The FDA advisory panel supported reclassifying six of seven peptides under review, despite the compounds lacking large, well-controlled trials needed to establish safety and effectiveness. These therapies are promoted for uses including injury recovery, muscle growth, fat loss and metabolism, while experts raised concerns about inconsistent formulations, limited safety data and potential risks.

The issue highlights the need for clear public communication as access and interest in peptides expand. Read more from NPR here.